Theresa Rehm-Hamilton
Physician Assistant · Mobile, ALNPI 1770711400
Payments from drug & device makers
Across 153 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$518
- E.r. Squibb & Sons, L.L.C.$354
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$132
- Johnson & Johnson$67
- Otsuka Pharmaceutical Development & Commercialization, Inc.$49
- plus $245 from 10 others
What the payments were for
- Speaking & faculty fees$1,25030%
- Food & beverage$2,86369%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 113 | $2,798 |
| Otsuka America Pharmaceutical, Inc. | 14 | $518 |
| E.r. Squibb & Sons, L.L.C. | 5 | $354 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $132 |
| Johnson & Johnson | 3 | $67 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $49 |
| OWP Pharmaceuticals, Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 3 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Corium, LLC | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,162 in reported general payments places this provider in the 85th percentile of 846 physician assistant providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $28,274 |
| Vilazodone Hcl | 21 | $2,414 |
| Buspirone Hcl | 11 | $360 |
| Escitalopram Oxalate | 20 | $201 |
| Lamotrigine | 17 | $169 |
| Bupropion Hcl SrBupropion Hcl | 14 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,798 | $28,27419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 physician assistant providers in Alabama.
Other physician assistant in Mobile
- Ashley PeaceMobile$27K
- Gregory SharpMobile$19K
- Elizabeth SimpsonMobile$18K
- Jessica DavisMobile$15K
- Alyssa HollingsworthMobile$14K
- Jessica KantralesMobile$14K
- Mary HneichMobile$12K
- James GunnMobile$10K
- Taryn ThompsonMobile$10K
- Hannah SmithMobile$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.